SavedAdd your journal

Journals / İstanbul Kuzey Klinikleri / 2018 / Cilt: 5 - Sayı: 1

Autoimmune Hemolytic Anemia Associated with Infliximab Infusion in Ulcerative Colitis

Veysel TAHAN
Fazia A. MİR
Alhareth Al JUBOORİ
Jack D. BRAGG
Pages
64–66
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Herein we report a case of drug-induced hemolytic anemia after infliximab infusion for treating ulcerative colitis.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Infliximab is a monoclonal antibody that antagonizes the activity of tumor necrosis factor alpha to induce and maintain remission in patients with inflammatory bowel disease.
📊
Key Findings & Data:Adverse effects associated with Infliximab infusions include infusion reactions, risk of infections, development of hematological malignancies, and pancytopenia.
💡
Conclusion & Impact:Herein we report a case of drug-induced hemolytic anemia after infliximab infusion for treating ulcerative colitis.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Infliximab is a monoclonal antibody that antagonizes the activity of tumor necrosis factor alpha to induce and maintain remission in patients with inflammatory bowel disease. Adverse effects associated with Infliximab infusions include infusion reactions, risk of infections, development of hematological malignancies, and pancytopenia. Autoimmune hemolytic anemia has rarely been reported in ulcerative colitis. Herein we report a case of drug-induced hemolytic anemia after infliximab infusion for treating ulcerative colitis.

🔖

Cite This Article

TAHAN, V., MİR, F. A., JUBOORİ, A. A., BRAGG, J. D. (2022). Autoimmune Hemolytic Anemia Associated with Infliximab Infusion in Ulcerative Colitis. İstanbul Kuzey Klinikleri, Cilt: 5 - Sayı: 1, 64–66. https://ajindex.com/articles/652037

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Rutgeerts P, Sandborn WJ, Feagan BG, Reinisch W, Olson A, Johanns J, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005;353:2462–76. Aronson JK. Meyler’s Side Effects of Analgesics and Anti-inflammatory Drugs. 1st ed. Elsevier; 2009.
  2. Chaudhary RK, Das SS. Autoimmune hemolytic anemia: From lab to bedside. Asian J Transfus Sci 2014;8:5–12.
  3. Gehrs BC, Friedberg RC. Autoimmune hemolytic anemia. Am J Hematol 2002;69:258–71.
  4. Leo Carnerero E, Aoufi S, Montero Cuadrado I, Herrera Martin P, Herrera Justiniano JM. Autoimmune hemolytic anemia associated with ulcerative colitis: response to infliximab. Am J Gastroenterol 2009;104:2370–1. Molnár T, Farkas K, Szepes Z, Nagy F, Wittmann T. Autoimmune hemolytic anemia associated with ulcerative colitis: the most important step is to induce complete remission. Am J Gastroenterol 2010;105:1203–4.
  5. Vermeire S, Noman M, Van Assche G, Baert F, Van Steen K, Esters N, et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn’s disease: a prospective cohort study. Gastroenterology 2003;125:32–9.
  6. Fidder H, Schnitzler F, Ferrante M, Noman M, Katsanos K, Segaert S, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study. Gut 2009;58:501–8.
  7. Vermeire S, Louis E, Carbonez A, Van Assche G, Noman M, Belaiche J, et al. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn’s disease. Am J Gastroenterol 2002;97:2357–63.
  8. Leo Carnerero E, Aoufi S, Montero Cuadrado I, Herrera Martin P, Herrera Justiniano JM. Autoimmune hemolytic anemia associated with ulcerative colitis: response to infliximab. Am J Gastroenterol 2009;104:2370–1.
  9. Leo-Carnerero E, Araujo-Míguez A, Trigo-Salado C, De-la-CruzRamírez MD, Herrera-Justiniano JM, Márquez-Galán JL. The effect of controlling inflammatory activity in the colon on the response to infliximab of autoimmune haemolytic anaemia associated with ulcerative colitis. Rev Esp Enferm Dig 2014;106:295–6.